Results from a controlled, randomised trial in UK concluded that concomitant vaccination with one of two SARS-CoV-2 vaccines (ChAdOx1 or BNT162b2) plus an age-appropriate influenza vaccine raised no safety concerns and preserves antibody responses to both vaccines. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02329-1/fulltext
Available vaccines in Europe
Vaccine composition
On 25 February 2022, WHO published recommendations for the components of influenza vaccines for use in the 2022-2023 northern hemisphere influenza season:
The WHO recommends that quadrivalent vaccines for use in the 2022-2023 influenza season in the northern hemisphere contain the following:
Egg-based Vaccines
• an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
• an A/Darwin/9/2021 (H3N2)-like virus;
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell culture- or recombinant-based Vaccines
• an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
• an A/Darwin/6/2021 (H3N2)-like virus;
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
The WHO recommended that trivalent vaccines for use in the 2022-2023 influenza season in the northern hemisphere contain the following:
Egg-based vaccines
• an A/Victoria/2570/2019 (H1N1)pdm09-like virus;
• an A/Darwin/9/2021 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell culture- or recombinant-based vaccines
• an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
• an A/Darwin/6/2021 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus
On 23 September 2022, WHO published recommendations for the components of influenza vaccines for use in the 2023 southern hemisphere influenza season:
Egg-based Vaccines
• an A/Sydney/5/2021 (H1N1)pdm09-like virus;
• an A/Darwin/9/2021 (H3N2)-like virus;
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Cell- or recombinant-based Vaccines
• an A/Sydney/5/2021 (H1N1)pdm09-like virus;
• an A/Darwin/6/2021 (H3N2)-like virus;
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
It was recommended that trivalent influenza vaccines for use in the 2023 southern hemisphere influenza season contain the following:
Egg-based vaccines
• an A/Sydney/5/2021 (H1N1)pdm09-like virus;
• an A/Darwin/9/2021 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell- or Recombinant-based vaccines
• an A/Sydney/5/2021 (H1N1)pdm09-like virus;
• an A/Darwin/6/2021 (H3N2)-like virus; and
• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus
The full report is published here.